---
title: "Erasca, Inc. Reports Q3 2025 Financial Results"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/265639743.md"
description: "Erasca, Inc. (ERAS) reported its Q3 2025 financial results, showing a net loss of $30.6 million, an improvement from a $31.2 million loss in Q3 2024. Operating expenses decreased to $34.5 million from $37.2 million. The company holds $362.4 million in cash and equivalents, supporting future R&D efforts. Erasca remains focused on developing therapies for RAS/MAPK pathway-driven cancers and is confident in its strategic direction and financial stability for the upcoming year."
datetime: "2025-11-13T04:21:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265639743.md)
  - [en](https://longbridge.com/en/news/265639743.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265639743.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/265639743.md) | [繁體中文](https://longbridge.com/zh-HK/news/265639743.md)


# Erasca, Inc. Reports Q3 2025 Financial Results

Erasca, Inc. ( (ERAS) ) has released its Q3 earnings. Here is a breakdown of the information Erasca, Inc. presented to its investors.

### Meet Your ETF AI Analyst

-   Discover how TipRanks' _ETF_ AI Analyst can help you make smarter investment decisions
-   Explore ETFs TipRanks' users love and see what insights the **_ETF_ AI Analyst** reveals about the ones you follow.

Erasca, Inc. is a clinical-stage precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers, operating primarily in the biotechnology sector. The company recently released its earnings report for the third quarter of 2025, highlighting its ongoing efforts in research and development and financial performance. Erasca reported a net loss of $30.6 million for the third quarter of 2025, slightly improving from a $31.2 million loss in the same period last year. The company’s operating expenses decreased to $34.5 million from $37.2 million, reflecting cost management efforts. Despite the losses, Erasca maintains a strong cash position with $362.4 million in cash, cash equivalents, and marketable securities, which it plans to use for future research and development activities. Looking ahead, Erasca remains committed to advancing its pipeline of oncology therapies, with management expressing confidence in the company’s strategic direction and financial stability to support its operations over the next year.

### 相关股票

- [Erasca (ERAS.US)](https://longbridge.com/zh-CN/quote/ERAS.US.md)

## 相关资讯与研究

- [What Happens Next After the QQQ ETF’s 3% Single-Day Move? Here’s What History Tells Us.](https://longbridge.com/zh-CN/news/281552388.md)
- [The 4 Questions Investors Should Ask Before Buying Any ETF](https://longbridge.com/zh-CN/news/281549873.md)
- [Insig AI Plans Growth Drive and Eyes Nasdaq Dual Listing](https://longbridge.com/zh-CN/news/281311983.md)
- [VegaShares Launches the First Multi-Index Covered Call Income ETF (ODTE) | ODTE Stock News](https://longbridge.com/zh-CN/news/281553894.md)
- [Cardinal Health Boosts Actinium-225 Production Capacity to Meet Demand for Novel Cancer Therapies](https://longbridge.com/zh-CN/news/281360890.md)